JPMorgan Chase & Co. has recruited senior healthcare investment banker David Blais from Guggenheim Securities, according to two people familiar with the decision.
Blais, who concentrates on mergers and acquisitions in the healthcare services sector, will be joining JPMorgan as a managing director later this month. One of the sources said he will report to the co-heads of healthcare investment banking, Jerry Lee and Nick Richitt.
Publicly available professional records and filings were cited in describing Blais's background. His LinkedIn profile indicates he has been with Guggenheim Securities since August 2014. FINRA records show that prior to his tenure at Guggenheim he served as a director in mergers and acquisitions at Citigroup and that he previously worked at JPMorgan between 2007 and 2010.
The report of the hire was attributed to two people familiar with the decision. The available information outlines Blais's role focus and employment history but does not provide further details on the terms of the move, such as compensation, an exact start date beyond the timing noted, or responsibilities beyond his reporting line.
Context and implications
The hiring brings an experienced healthcare services M&A banker into JPMorgan's healthcare team and reintroduces an executive with prior experience at the bank. The move, as described by the sources and public records, underscores a personnel change within the bank's healthcare investment banking ranks but does not provide additional commentary from JPMorgan or Guggenheim in the available information.
Information sources
- Two people familiar with the decision provided the initial report of the hire.
- Blais's LinkedIn profile supplies the tenure at Guggenheim Securities beginning August 2014.
- FINRA records list earlier roles, including a director position in mergers and acquisitions at Citigroup and prior employment at JPMorgan from 2007 to 2010.
The facts presented are limited to those reported by the sources and those available in the cited professional records. No additional assertions about the strategic rationale, compensation, or broader market reaction are included in the available information.